General Information
edit

Website	suppremol.com
Category	BioTech
Phone	49-(0)89-30-90-50-680
Email	info@suppremol.com
Employees

Offices
edit

Munich, DEU

Am Klopferspitz 19
Munich, 82152, DEU

People
edit

Klaus Schollmeier

Chief Executive Officer

Funding
edit

TOTAL	$37.9M
FUNDING TOTAL	$37.9M
Series A, 5/06 KfW Mittelstandsbank Bayern Kapital Z-Cube	$5.15M
Series C, 12/10 BioMedPartners MIG AG Santo Holding KfW Mittelstandsbank Bayern Kapital FCP Biotech Holding	€15.5M
Series D, 5/13 MIG AG Santo Holding BioMedPartners FCP Biotech Holding	€9.5M

Tags
edit

SuppreMol
edit

SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

Recent Milestones
edit

SuppreMol received $12.2M (€9.5M) in Series D funding. (5/21/13)

Posted 5/21/13 at 7:12pm via dowjones.com
SuppreMol received $20.6M (€15.5M) in Series C funding. (12/17/10)

Posted 12/19/10 at 6:56pm via finsmes.com
SuppreMol received $5.15M in Series A funding. (5/24/06)

Posted 4/27/10 at 12:31am
SuppreMol added Klaus Schollmeier as Chief Executive Officer.

Posted 4/9/13 at 4:53am